Pappas CapitalPappas CapitalPappas CapitalPappas Capital
  • Home
  • About 
    • About Us
    • News & Events
    • For Entrepreneurs
    • Contact Us
  • Team
  • Portfolio
  • Ventures
  • Specialized Funds 
    • About
    • Chiesi Ventures Fund
    • Specialized Holdings
  • Translational Medicine 
    • About
    • Wake Forest Technology Development Program

Chiesi

Chiesi

Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics

BioAtla Announces Pricing of Initial Public Offering

4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering

Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth

Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

VelosBio to be Acquired by Merck for $2.75 billion

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat

Kyle Rasbach will serve on a panel at the World Orphan Drug Congress USA 2020

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa

pcopu - June 18, 2018 - No Comments
logo_white
  • Home
  • About
  • Team
  • Portfolio
  • News & Events
  • Contact
  • Ventures
  • Specialized Funds
  • Translational Medicine
NVCA
bio
nc-biotech

© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.

Investor Login
Investor Login

© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.